{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"5.9","value":"0.60"},{"groupId":"OG001","lowerLimit":"0.2","upperLimit":"2.4","value":"0.80"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"0.7","value":"0.50"},{"groupId":"OG003","lowerLimit":"0.5","upperLimit":"0.7","value":"0.60"},{"groupId":"OG004","lowerLimit":"1.1","upperLimit":"5.7","value":"3.20"},{"groupId":"OG005","lowerLimit":"0.1","upperLimit":"2.1","value":"1.40"}]}],"title":"Baseline (Predose)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"4.8","value":"2.50"},{"groupId":"OG001","lowerLimit":"0.2","upperLimit":"9.5","value":"3.90"},{"groupId":"OG002","lowerLimit":"27.8","upperLimit":"29.6","value":"28.70"},{"groupId":"OG003","lowerLimit":"5","upperLimit":"28.6","value":"16.80"},{"groupId":"OG004","lowerLimit":"1.7","upperLimit":"71.3","value":"13.50"},{"groupId":"OG005","lowerLimit":"1","upperLimit":"47","value":"3.40"}]}],"title":"Day 1 (Postdose)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"description":"Bound samalizumab was detected using a monoclonal antibody (mAb) specific for samalizumab. The binding of samalizumab to CD200 on peripheral B-CLL tumor cells was evaluated in participants with B-CLL by flow cytometry and expressed as the percent of B-CLL cells bound by samalizumab. For participants with insufficient numbers of peripheral B-CLL for analysis, the samples were documented as \"unevaluable\" and an analysis was not performed.","dispersionType":"Full Range","groups":[{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 50 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG000","title":"Samalizumab 50 mg/m^2"},{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 100 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG001","title":"Samalizumab 100 mg/m^2"},{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 200 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG002","title":"Samalizumab 200 mg/m^2"},{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 300 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG003","title":"Samalizumab 300 mg/m^2"},{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 400 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG004","title":"Samalizumab 400 mg/m^2"},{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 500 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG005","title":"Samalizumab 500 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"All participants with B-CLL who had evaluable assessments for bound samalizumab were included in the analysis. No participants with B-CLL received samalizumab at the 600 mg/m\\^2 dose level.","reportingStatus":"POSTED","timeFrame":"Baseline (Predose) and Day 1 (Postdose)","title":"Percent Of Bound Samalizumab On B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells In Participants With B-CLL At Baseline (Predose) And Day 1 (Postdose)","type":"SECONDARY","unitOfMeasure":"percentage of B-CLL cells bound"}